Clinical trial
Factor VIIa in Acute Intracerebral Haemorrhage
NCT00266006 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00266006 |
|---|---|
| Title | Factor VIIa in Acute Intracerebral Haemorrhage |
| Official title | Safety of Eptacog Alfa (Activated) (Genetical Recombination) on Adverse Events and Serious Adverse Events in Patients With Acute Intracerebral Haemorrhage. |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acquired Bleeding Disorder, Intracerebral Haemorrhage |
| Intervention type | Drug |
| Interventions | eptacog alfa (activated) |
| Enrollment | 90 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Dec 15, 2005 |
| Last update posted | Nov 18, 2016 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: